<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Surg</journal-id><journal-id journal-id-type="iso-abbrev">Int J Surg</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">JS9</journal-id><journal-title-group><journal-title>International Journal of Surgery (London, England)</journal-title></journal-title-group><issn pub-type="ppub">1743-9191</issn><issn pub-type="epub">1743-9159</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430749</article-id><article-id pub-id-type="pmcid-ver">PMC12430749.1</article-id><article-id pub-id-type="pmcaid">12430749</article-id><article-id pub-id-type="pmcaiid">12430749</article-id><article-id pub-id-type="pmid">40717575</article-id><article-id pub-id-type="doi">10.1097/JS9.0000000000002656</article-id><article-id pub-id-type="publisher-id">IJS-D-25-02554</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group></article-categories><title-group><article-title>Neuroendocrine carcinoma of the bladder: do they have a worse prognosis? A large retrospective cohort study by propensity score matching analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1372-4596</contrib-id><name name-style="western"><surname>Liu</surname><given-names initials="L">Liang</given-names></name><degrees>MD</degrees><email>mnwkll@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>He</surname><given-names initials="LY">Li-Ya</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="PY">Pan-Ying</given-names></name><degrees>MS</degrees><email>zhangpy666@126.com</email><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiao</surname><given-names initials="Y">Yu</given-names></name><degrees>MD</degrees><email>xiaoy3@outlook.com</email><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wei</surname><given-names initials="D">Dong</given-names></name><degrees>MS</degrees><email>weidong051222@sina.com</email><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Su</surname><given-names initials="RP">Rui-Ping</given-names></name><degrees>MD</degrees><xref rid="aff6" ref-type="aff">
<sup>f</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Urology Department, Chongqing Emergency Medical Center, Chongqing University Central Hospital, Chongqing University, Chongqing, China</aff><aff id="aff2"><label>b</label>The Fifth Department of Oncology, Hebei General Hospital, Shijiazhuang, China</aff><aff id="aff3"><label>c</label>Department of Urology, Hebei General Hospital, Shijiazhuang, China</aff><aff id="aff4"><label>d</label>Psychosomatic Medical Center, The Fourth People&#8217;s Hospital of Chengdu, Chengdu, China</aff><aff id="aff5"><label>e</label>Psychosomatic Medical Center, The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China</aff><aff id="aff6"><label>f</label>Department of Urology, Urology and Nephrology Hospital, Xi&#8217;an People&#8217;s Hospital (Xi&#8217;an Fourth Hospital), Xi&#8217;an, China</aff></contrib-group><author-notes><corresp id="COR0001"><label>*</label>Corresponding authors. Address: Urology department, Chongqing Emergency Medical Center, Chongqing University Central Hospital, Chongqing University, Chongqing 400015, China. Tel.: +023 6369 2122. E-mail: <email>mnwkll@163.com</email> (L. Liu); Department of Urology, Urology and Nephrology Hospital, Xi&#8217;an People&#8217;s Hospital (Xi&#8217;an Fourth Hospital), Xi&#8217;an 710004, China. Tel.: +029 6119 9095. E-mail: <email>820218035@qq.com</email> (R.-P. Su).</corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>15</day><month>7</month><year>2025</year></pub-date><volume>111</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496813</issue-id><fpage>6435</fpage><lpage>6440</lpage><history><date date-type="received"><day>22</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0</ext-link> (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="js9-111-6435.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="js9-111-6435.pdf"/><abstract><sec><title>Background:</title><p>The aim was to develop nomograms by integrating clinical characteristics and treatment data to predict overall survival (OS) and cancer-specific survival (CSS) for bladder patients including urothelial carcinoma (UC) and neuroendocrine bladder cancer (NEBC).</p></sec><sec><title>Methods:</title><p>We utilized the Surveillance, Epidemiology, and End Results (SEER) database (2004&#8211;2015) to compare the OS and CSS between NEBC and UC. Multivariable Cox analyses and propensity score matching (PSM) were employed for analysis. Then, we developed nomograms based on multivariate analysis. Kaplan&#8211;Meier curves were used to analyze the OS and CSS, and curves&#8217; differences were compared by the log-rank test.</p></sec><sec><title>Result:</title><p>The median OS for NEBC patients who underwent transurethral resection of bladder tumor (TURBT) was 15&#160;months, compared to 11&#160;months for UC patients after PSM (<italic toggle="yes">P</italic> =&#160;0.001). Similarly, the median OS for patients who underwent radical cystectomy was 25&#160;months for NEBC and 70&#160;months for UC (<italic toggle="yes">P</italic> =&#160;0.001). The median CSS for NEBC patients who did not receive treatment was 7&#160;months, while it was 13&#160;months for those who underwent TURBT, 33&#160;months for those who underwent RC, and 15&#160;months for those who received other medical treatments. Multivariate Cox regression revealed that histological type, age at diagnosis, married, race, stage_T, stage_N, stage_M, and surgery were independent prognostic factors for OS and CSS. Multivariate analysis also indicated that chemotherapy was independent prognostic factors for OS. Then, we developed nomograms to assist clinicians in more accurately predicting 1-year, 3-year, and 5-years OS and CSS rate.</p></sec><sec><title>Conclusion:</title><p>Compared with UC, NEBC has shorter overall survival and cancer specific survival. Besides, histological type, age at diagnosis, married, race, stage_T, stage_N, stage_M, surgery and chemotherapy were the independent prognostic factors for overall survival, while histological type, age at diagnosis, married, race, stage_T, stage_N, stage_M and surgery were independent prognostic factors for cancer specific survival. We developed and confirmed first nomograms including treatment information to forecast 1-year, 3-year, and 5-year OS and CSS for patients. These results should guide the development of consensus best practice guidelines for treating and managing NEBC patients.</p></sec></abstract><kwd-group><kwd>carcinoma</kwd><kwd>neuroendocrine</kwd><kwd>prognosis</kwd><kwd>propensity score matching</kwd><kwd>urinary bladder neoplasms</kwd><kwd>urothelial carcinoma</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Bladder cancer (BCa), divided into urothelial and non-urothelial tumors, has a high mortality and morbidity. The etiology of BCa is complex, and the currently study mainly focuses on urothelial carcinoma (UC). Neuroendocrine bladder cancer (NEBC) is particularly rare tumor with poor prognosis. It was reported that compared with UC, the type of pure small cell has a worse prognosis, and 5-year survival rates are 8&#8211;16%<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup>.</p><p>NEBC has a high degree of malignancy. However, diagnosis of NEBC is often missed in clinical practice due to its low incidence. In recent years, the detection rate of NEBC has been steadily increasing, attributed to the development of diagnosis technology and enhanced health awareness. It has been demonstrated that NEBC have a poor prognosis, and found some factors are associated with a worse prognosis<sup>[<xref rid="R2" ref-type="bibr">2</xref>-<xref rid="R4" ref-type="bibr">4</xref>]</sup>. However, those studies are retrospective analysis or small sample size, and failed to adequately control for confounders. Therefore, there was controversy surrounding the conclusions of these studies.</p><p>In this study, we conducted a retrospective analysis of the clinicopathological features and survival data of NEBC patients using the Surveillance, Epidemiology, and End Results (SEER) database to verify their clinicopathological traits and prognostic factors. Besides, to ensure more trustworthy results, propensity score matching analysis (PSM) was used to minimize the effect of bias in patient selection. Ultimately, we developed nomograms to assist clinicians in more accurately predicting 1, 3, and 5&#160;years overall survival (OS) and cancer specific survival (CSS).</p></sec><sec sec-type="methods"><title>Materials and methods</title><p>This article is compliant with the TITAN Guidelines 2025 &#8211; governing declaration and use of AI.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> The patient information was accessed from the SEER database by SEER*Stat 8.4.1.2 following approval and permission from SEER. Since SEER is a public database, informed consent and institutional approval aren&#8217;t required. Patients diagnosed with primary NEBC and bladder UC by histologically firstly (C67) in 2004&#8211;2015&#160;years, age of diagnosis &#8805;20&#160;years were included. Besides, patients with incomplete clinical information such as race, marital status at diagnosis, TNM staging (American Joint Committee on Cancer [AJCC] Staging Manual [sixth edition]), grade and survival time, and survival time less than 1 month were excluded from this study. Figure S1 (Supplemental Digital Content 4, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E642" ext-link-type="uri">http://links.lww.com/JS9/E642</ext-link>) shows the patient selection flowchart. This study incorporated fifteen clinical variables categorized into four main domains: demographics (sex, age at diagnosis, race, and marital status at diagnosis), tumor characteristics (grade, histological type, and AJCC stage), treatment details (surgery of the primary site, radiation therapy, and chemotherapy), and survival outcomes (survival status, OS, and CSS) (Table S1, Supplemental Digital Content 1, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E642" ext-link-type="uri">http://links.lww.com/JS9/E642</ext-link>). This study followed Strengthening the Reporting of Cohort, Cross Sectional, and Case&#8211;Control Studies in Surgery (STROCSS) criteria<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup>. Furthermore, we performed propensity-score matching analyses to minimize the influence of possible confounding variables between NEBC and UC patients. The matching variables included age at diagnosis, marital status, and TNM staging. The nearest-neighbor technique was employed for 1:1 matching, with a caliper value of 0.00001.</p><p>Categorical variables, expressed as n (%), were evaluated using the chi-square test. The OS and CSS curves were plotted using the Kaplan&#8211;Meier method, and the log-rank test was used to compare the differences between them. Univariate and multivariate Cox regression were used to analyze the prognostic factors of OS and CSS. Then, the OS and CSS prediction models were constructed according to the multivariate Cox regression. <italic toggle="yes">P</italic> &lt;0.05 was considered statistically significant. Nomograms were drawn using the R language, while other statistical analyses were carried out using SPSS 25.0.</p></sec><sec sec-type="results"><title>Result</title><p>A total of 121&#160;319 patients including 120,486 UC patients and 833 NEBC patients met our study. The majority of NEBC patients were male (75.5%), aged 60&#160;years or over (83.8%), Caucasian (89.9%), and married (59.2%). Besides, 83.9% NEBC patients had a muscle-invasive bladder cancer (MIBC) diagnosis, while only 20.8% and 20.8% developed regional lymph node invasion and distant metastasis. For treatment, NEBC patients primarily received TURBT (n&#160;=&#160;467, 56.1%) or radical cystectomy (n&#160;=&#160;262, 31.5%). Most patients (n&#160;=&#160;534, 64.1%) had chemotherapy and 27.0% received radiation. At the end of follow-up period, 699 (83.9%) NEBC patients had died and 530 (63.6%) deaths were related to the BCa. However, 65,270 (54.2%) UC patients were dead and only 25,801 (21.4%) deaths were related to the BCa. There were statistical differences in several baseline clinicopathological features such as age, marital status, and TNM staging between the groups before matching. Table S1 (Supplemental Digital Content 1, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E642" ext-link-type="uri">http://links.lww.com/JS9/E642</ext-link>) shows the clinicopathological features, treatment therapies, survival and prognosis between NEBC and UC patients before propensity score match (PSM). There were no statistical differences in age, marital status, and TNM staging between the groups after matching. Table S2 (Supplemental Digital Content 2, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E642" ext-link-type="uri">http://links.lww.com/JS9/E642</ext-link>) shows the clinicopathological features, treatment therapies, survival and prognosis between NEBC and UC patients after PSM.<boxed-text id="UBT0001" position="float" orientation="portrait"><sec><title>HIGHLIGHTS</title><p><list list-type="bullet"><list-item><p>This study represents the first application of propensity-score matching (PSM) to analyze prognostic factors in neuroendocrine bladder cancer (NEBC).</p></list-item><list-item><p>Compared to bladder urothelial carcinoma, NEBC exhibited worse overall survival (OS) and cancer-specific survival (CSS).</p></list-item><list-item><p>Histological type, age at diagnosis, married, race, stage_T, stage_N, stage_M, surgery and chemotherapy were the independent prognostic factors for overall survival, while histological type, age at diagnosis, married, race, stage_T, stage_N, stage_M and surgery were independent prognostic factors for cancer specific survival.</p></list-item><list-item><p>We developed and confirmed first nomograms including treatment information to forecast 1-year, 3-year, and 5-year OS and CSS for patients.</p></list-item></list></p></sec></boxed-text></p><p>Univariate Cox regression showed that age at diagnosis, marital status, race, TNM staging, surgery, radiation, and histological type were closely associated with OS and CSS (<italic toggle="yes">P</italic> &lt; 0.05). Besides, results revealed that chemotherapy was significantly associated with OS but not CSS (<italic toggle="yes">P</italic> &lt; 0.05). Table S3 (Supplemental Digital Content 3, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E642" ext-link-type="uri">http://links.lww.com/JS9/E642</ext-link>) shows the concrete results of univariate analysis. Multivariate Cox regression revealed that histological type (NEBC vs. UC: HR&#160;=&#160;1.421, 95%CI&#160;=&#160;1.268&#8211;1.594, <italic toggle="yes">P</italic> &lt; 0.001), age at diagnosis (60-84 year vs.&#160;&lt;&#160;60 year: HR&#160;=&#160;1.135, 95%CI&#160;=&#160;1.137&#8211;1.567, <italic toggle="yes">P</italic> &lt; 0.001;&#160;&gt;&#160;84 year vs.&#160;&lt;&#160;60 year: HR&#160;=&#160;1.803, 95%CI&#160;=&#160;1.803&#8211;2.787, <italic toggle="yes">P</italic> &lt; 0.001), married (HR&#160;=&#160;0.771, 95%CI&#160;=&#160;0.649&#8211;0.915, <italic toggle="yes">P</italic> =&#160;0.003), race (black vs. white: HR&#160;=&#160;1.226, 95%CI&#160;=&#160;1.008&#8211;1.492, <italic toggle="yes">P</italic> =&#160;0.042; others vs. white: HR&#160;=&#160;0.677, 95%CI&#160;=&#160;0.541&#8211;0.847, <italic toggle="yes">P</italic> =&#160;0.001), stage_T (MIBC vs. NMIBC: HR&#160;=&#160;1.452, 95%CI&#160;=&#160;1.243&#8211;1.695, <italic toggle="yes">P</italic> &lt; 0.001), stage_N (N+&#160;vs. N0: HR&#160;=&#160;1.586, 95%CI&#160;=&#160;1.375&#8211;1.828, <italic toggle="yes">P</italic> &lt; 0.001), stage_M (M1 vs. M0: HR&#160;=&#160;2.660, 95%CI&#160;=&#160;2.298&#8211;3.079, <italic toggle="yes">P</italic> &lt; 0.001), surgery (RC vs. none: HR&#160;=&#160;0.567, 95%CI&#160;=&#160;0.420&#8211;0.765, <italic toggle="yes">P</italic> &lt; 0.001), and chemotherapy (HR&#160;=&#160;0.654, 95%CI&#160;=&#160;0.577&#8211;0.741, <italic toggle="yes">P</italic> &lt; 0.001) were independent prognostic factors for OS. Furthermore, multivariate analysis also indicated that histological type (NEBC vs. UC: HR&#160;=&#160;1.299, 95%CI&#160;=&#160;1.143&#8211;1.476, <italic toggle="yes">P</italic> &lt; 0.001), age at diagnosis (&gt;84 year vs.&#160;&lt;&#160;60 year: HR&#160;=&#160;1.943, 95%CI&#160;=&#160;1.519&#8211;2.486, <italic toggle="yes">P</italic> &lt; 0.001), married (HR&#160;=&#160;0.785, 95%CI&#160;=&#160;0.645&#8211;0.955, <italic toggle="yes">P</italic> =&#160;0.016), race (black vs. white: HR&#160;=&#160;1.253, 95%CI&#160;=&#160;1.004&#8211;1.565, <italic toggle="yes">P</italic> =&#160;0.046; others vs. white: HR&#160;=&#160;0.694, 95%CI&#160;=&#160;0.533&#8211;0.905, <italic toggle="yes">P</italic> =&#160;0.007), stage_T (MIBC vs. NMIBC: HR&#160;=&#160;1.641, 95%CI&#160;=&#160;1.355&#8211;1.989, <italic toggle="yes">P</italic> &lt; 0.001), stage_N (N+&#160;vs. N0: HR&#160;=&#160;1.702, 95%CI&#160;=&#160;1.457&#8211;1.989, <italic toggle="yes">P</italic> &lt; 0.001), stage_M (M1 vs. M0: HR&#160;=&#160;2.649, 95%CI&#160;=&#160;2.263&#8211;3.102, <italic toggle="yes">P</italic> &lt; 0.001), surgery (RC vs. none: HR&#160;=&#160;0.481, 95%CI&#160;=&#160;0.346&#8211;0.667, <italic toggle="yes">P</italic> &lt; 0.001) were independent prognostic factors for CSS. Table <xref rid="T1" ref-type="table">1</xref> shows the concrete results of multivariate analysis. Then, we developed nomograms to assist clinicians in more accurately predicting 1-year, 3-year, and 5-years OS and CSS rate (Fig. <xref rid="F1" ref-type="fig">1</xref>A and B).
<fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>(A) Nomograms predicting OS of bladder cancer patients after PSM. (B) Nomograms predicting CSS of bladder cancer patients after PSM. (C) OS of bladder cancer patients after PSM in the NEBC group and UC group. (D) CSS of bladder cancer patients after PSM in the NEBC group and UC group. Note: NEBC: neuroendocrine carcinoma; UC: urothelial carcinoma; SDW: separated&#160;+&#160;divorced&#160;+&#160;widowed; NMIBC: non-muscle-invasive bladder cancer; MIBC: muscle-invasive bladder cancer; TURBT: transurethral resection of bladder tumor; RC: radical cystectomy; OS: overall survival; CSS: cancer-specific survival; PSM: propensity score match.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6435-g001.jpg"/></fig>
<fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>OS and CSS in surgery after PSM in the NEBC group and UC group. Note: NEBC: neuroendocrine carcinoma; UC: urothelial carcinoma; TURBT: transurethral resection of bladder tumor; RC: radical cystectomy; OS: overall survival; CSS: cancer-specific survival; PSM: propensity score match.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6435-g002.jpg"/></fig>
<table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Multivariate analysis of overall survival and cancer specific survival after PSM</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="center" colspan="3" rowspan="1">Overall survival</th><th align="center" colspan="3" rowspan="1">Cancer specific survival</th></tr><tr><th align="center" rowspan="1" colspan="1">HR</th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th align="center" rowspan="1" colspan="1">HR</th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Histological type</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;UC</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;NEBC</td><td align="left" rowspan="1" colspan="1">1.421</td><td align="left" rowspan="1" colspan="1">1.268, 1.594</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">1.299</td><td align="left" rowspan="1" colspan="1">1.143, 1.476</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, year</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;60</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;60&#8211;84</td><td align="left" rowspan="1" colspan="1">1.135</td><td align="left" rowspan="1" colspan="1">1.137, 1.567</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">1.163</td><td align="left" rowspan="1" colspan="1">0.974, 1.389</td><td align="left" rowspan="1" colspan="1">0.094</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&gt;84</td><td align="left" rowspan="1" colspan="1">2.241</td><td align="left" rowspan="1" colspan="1">1.803, 2.787</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">1.943</td><td align="left" rowspan="1" colspan="1">1.519, 2.486</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Marital status</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Single</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Married</td><td align="left" rowspan="1" colspan="1">0.771</td><td align="left" rowspan="1" colspan="1">0.649, 0.915</td><td align="left" rowspan="1" colspan="1">0.003</td><td align="left" rowspan="1" colspan="1">0.785</td><td align="left" rowspan="1" colspan="1">0.645, 0.955</td><td align="left" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;SDW</td><td align="left" rowspan="1" colspan="1">0.928</td><td align="left" rowspan="1" colspan="1">0.772, 1.115</td><td align="left" rowspan="1" colspan="1">0.427</td><td align="left" rowspan="1" colspan="1">0.957</td><td align="left" rowspan="1" colspan="1">0.774, 1.182</td><td align="left" rowspan="1" colspan="1">0.681</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;White</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Black</td><td align="left" rowspan="1" colspan="1">1.226</td><td align="left" rowspan="1" colspan="1">1.008, 1.492</td><td align="left" rowspan="1" colspan="1">0.042</td><td align="left" rowspan="1" colspan="1">1.253</td><td align="left" rowspan="1" colspan="1">1.004, 1.565</td><td align="left" rowspan="1" colspan="1">0.046</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Others</td><td align="left" rowspan="1" colspan="1">0.677</td><td align="left" rowspan="1" colspan="1">0.541, 0.847</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">0.694</td><td align="left" rowspan="1" colspan="1">0.533, 0.905</td><td align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage_T</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;NMIBC</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Tis</td><td align="left" rowspan="1" colspan="1">0.245</td><td align="left" rowspan="1" colspan="1">0.034, 1.754</td><td align="left" rowspan="1" colspan="1">0.161</td><td align="left" rowspan="1" colspan="1">0.466</td><td align="left" rowspan="1" colspan="1">0.065, 3.344</td><td align="left" rowspan="1" colspan="1">0.447</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;MIBC</td><td align="left" rowspan="1" colspan="1">1.452</td><td align="left" rowspan="1" colspan="1">1.243, 1.695</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">1.641</td><td align="left" rowspan="1" colspan="1">1.355, 1.989</td><td align="left" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage_N</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N0</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N+</td><td align="left" rowspan="1" colspan="1">1.586</td><td align="left" rowspan="1" colspan="1">1.375, 1.828</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">1.702</td><td align="left" rowspan="1" colspan="1">1.457, 1.989</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage_M</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;M0</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;M1</td><td align="left" rowspan="1" colspan="1">2.660</td><td align="left" rowspan="1" colspan="1">2.298, 3.079</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">2.649</td><td align="left" rowspan="1" colspan="1">2.263, 3.102</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Surgery</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;None</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;TURBT</td><td align="left" rowspan="1" colspan="1">0.949</td><td align="left" rowspan="1" colspan="1">0.714, 1.260</td><td align="left" rowspan="1" colspan="1">0.716</td><td align="left" rowspan="1" colspan="1">0.865</td><td align="left" rowspan="1" colspan="1">0.637, 1.174</td><td align="left" rowspan="1" colspan="1">0.352</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;RC</td><td align="left" rowspan="1" colspan="1">0.567</td><td align="left" rowspan="1" colspan="1">0.420, 0.765</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">0.481</td><td align="left" rowspan="1" colspan="1">0.346, 0.667</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Others</td><td align="left" rowspan="1" colspan="1">0.905</td><td align="left" rowspan="1" colspan="1">0.647, 1.267</td><td align="left" rowspan="1" colspan="1">0.561</td><td align="left" rowspan="1" colspan="1">0.846</td><td align="left" rowspan="1" colspan="1">0.584, 1.227</td><td align="left" rowspan="1" colspan="1">0.379</td></tr><tr><td align="left" rowspan="1" colspan="1">Radiation</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;None/unknown</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.084</td><td align="left" rowspan="1" colspan="1">0.944, 1.245</td><td align="left" rowspan="1" colspan="1">0.253</td><td align="left" rowspan="1" colspan="1">0.889</td><td align="left" rowspan="1" colspan="1">0.762, 1.038</td><td align="left" rowspan="1" colspan="1">0.138</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemotherapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No/unknown</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">0.654</td><td align="left" rowspan="1" colspan="1">0.577, 0.741</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tbl1-fn1"><p>NEBC: neuroendocrine carcinoma; UC: urothelial carcinoma; SDW: separated&#160;+&#160;divorced&#160;+&#160;widowed; NMIBC: non-muscle-invasive bladder cancer; MIBC: muscle-invasive bladder cancer; TURBT: transurethral resection of bladder tumor; RC: radical cystectomy; OS: overall survival; CSS: cancer-specific survival; HR: hazard ratio; CI: confidence interval; PSM: propensity score match.</p></fn></table-wrap-foot></table-wrap>
</p><p>The OS and CSS rate with neuroendocrine carcinoma were significantly shorter than that of those with UC (OS median survival: 13&#160;months vs. 23&#160;months, <italic toggle="yes">P</italic> &lt; 0.001; CSS median survival: 17&#160;months vs. 37&#160;months, <italic toggle="yes">P</italic> &lt; 0.001; Fig. <xref rid="F1" ref-type="fig">1</xref>C and D). To evaluate the impact of treatment modalities on prognosis, we performed stratified analyses. After PSM, the median OS for untreated NEBC and UC patients was 3&#160;months and 7&#160;months, respectively (<italic toggle="yes">P</italic> =&#160;0.581; Fig. 2A). The median OS for NEBC patients who underwent transurethral resection of bladder tumor (TURBT) was 15&#160;months, compared to 11&#160;months for UC patients (<italic toggle="yes">P</italic> =&#160;0.001; Fig. 2B). Similarly, the median OS for patients who underwent radical cystectomy was 25&#160;months for NEBC and 70&#160;months for UC (<italic toggle="yes">P</italic> =&#160;0.001; Fig. 2C). The median OS for patients receiving other medical treatments was 12&#160;months for NEBC and 18&#160;months for UC (<italic toggle="yes">P</italic> =&#160;0.128; Fig. 2D). The median CSS for NEBC patients who did not receive treatment was 7&#160;months, while it was 13&#160;months for those who underwent TURBT, 33&#160;months for those who underwent RC, and 15&#160;months for those who received other medical treatments (Fig. 2E&#8211;H). To further investigate the impact of surgery on NEBC prognosis, we generated Kaplan&#8211;Meier survival curves following PSM (Figure S2, Supplemental Digital Content 5A and B, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E642" ext-link-type="uri">http://links.lww.com/JS9/E642</ext-link>). Our analysis revealed that a better prognosis was observed for NEBC patients received radical cystectomy, neither in OS, nor in CSS (log-rank <italic toggle="yes">P</italic> &lt; 0.001). Besides, comparing to without chemotherapy group, patients receiving chemotherapy presented longer OS (median survival: 18&#160;months vs. 7&#160;months, <italic toggle="yes">P</italic> &lt; 0.001) and CSS (median survival: 25&#160;months vs. 11&#160;months, <italic toggle="yes">P</italic> &lt; 0.001) (Figure S2, Supplemental Digital Content 5C and D, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E642" ext-link-type="uri">http://links.lww.com/JS9/E642</ext-link>).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>NEBC is a very rare malignancy, which present a significant challenge in terms of diagnosis and treatment for clinicians. The SEER database offers valuable strengths for addressing these challenges. In studies on rare tumors, particularly those involving surgery, radiation, and chemotherapy, SEER provides researchers with a large sample size, facilitating the identification of factors influencing patient survival. Propensity score matching is a statistical method employed to minimize potential bias and baseline differences, facilitating a more accurate comparison between study and control groups. In our study, firstly, we identified that neuroendocrine tumor having a particularly poor prognosis with shorter OS and CSS compared with urothelial carcinomas according to PSM. Besides, we also demonstrated that other factors which affect the BCa outcomes. Furthermore, age at diagnosis, married, race, stage_T, stage_N, stage_M, surgery and chemotherapy were independent prognostic factors for OS of BCa patients, while age at diagnosis, married, race, stage_T, stage_N, stage_M and surgery were independent prognostic factors for CSS of BCa patients. Then, we create a practical and all-encompassing nomogram model that incorporates treatment details, to predict the 1-year, 3-year, and 5-year OS and CSS for patients. With the help of the nomogram, clinicians can more accurately recognize patients with diverse prognoses, thereby providing more individualized treatment and follow-up strategies for NEBC and UC patients.</p><p>Due to the rarity and aggressive characteristics of NEBC, the optimal treatment schedule is not clearly defined. Surgery treatment significantly contributes to the treatment of NEBC, however, we do not currently recommend surgery alone. In our cohort, only 29 (3.5%) of patients don&#8217;t receive surgery while 803 (96.5%) of patients undergo surgery, including 467 (56.1%) who undergo TURBT, 261 (31.4%) who undergo RC, and 75 (9.0%) who undergo other surgical modalities. Some factors might be influencing the situation. To obtain better quality of life, many patients diagnosed with muscle-invasive bladder cancers refused RC. Therefore, for patients expected to live significantly longer than 5&#160;years, we recommend aggressive surgical procedures. A previous study[<xref rid="R7" ref-type="bibr">7</xref>] suggested that the combination of RC and perioperative chemotherapy or chemoradiotherapy could enhance patient survival. In addition, many other retrospective studies[<xref rid="R8" ref-type="bibr">8</xref>] have indicated that patients with bladder cancer and NEBC who received chemotherapy had a much better OS than those who did not.</p><p>In recent years, targeted therapy, immunotherapy, and other approaches have been increasingly used in the treatment of malignant tumors, thanks to the detailed study of their molecular genetics. Cancer immunotherapy, seen as the most promising future cancer medicine, is also displaying favorable therapeutic results for NEBC patients. Anti-PD-L1 and anti-PD-1 antibodies have been approved, giving new treatment possibilities to patients who are not candidates for cisplatin-based chemotherapy or have had unsuccessful treatments[<xref rid="R9" ref-type="bibr">9</xref>]. Research is also investigating the application of dual checkpoint inhibitors for non-urothelial bladder cancer.[<xref rid="R10" ref-type="bibr">10</xref>] Research has indicated that checkpoint inhibitors positively influence small-cell bladder carcinoma. A retrospective study shows that checkpoint inhibitors can improve the survival rate of patients with refractory to second-line therapy.[<xref rid="R11" ref-type="bibr">11</xref>]</p><p>Despite having a sufficiently large sample size to draw conclusions, this study had certain limitations. Firstly, this research was conducted retrospectively, which could have introduced selection bias. At the same time, innovative treatments like robot-assisted surgery, neoadjuvant chemotherapy, and molecular targeted therapy were important factors but were missing from the SEER database.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Firstly, compared with bladder urothelial carcinoma, neuroendocrine bladder cancer has shorter overall survival and cancer specific survival. Secondly, histological type, age at diagnosis, married, race, stage_T, stage_N, stage_M, surgery and chemotherapy were the independent prognostic factors for overall survival, while histological type, age at diagnosis, married, race, stage_T, stage_N, stage_M and surgery were independent prognostic factors for cancer specific survival. Finally, we developed and confirmed first nomogram including treatment information to forecast 1-year, 3-year, and 5-year OS and CSS for patients. These results should guide the development of consensus best practice guidelines for treating and managing NEBC patients.</p></sec></body><back><fn-group><fn fn-type="other"><p>Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal&#8217;s website, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.lww.com/international-journal-of-surgery" ext-link-type="uri">www.lww.com/international-journal-of-surgery</ext-link>.</p></fn><fn fn-type="equal"><p>Published online 15 July 2025</p></fn></fn-group><sec><title>Ethical approval</title><p>This is an observational study and no ethical approval is required. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The SEER Program collects data from population based cancer registries with anonymous information.</p></sec><sec><title>Consent</title><p>Not applicable.</p></sec><sec><title>Sources of funding</title><p>This study was supported by grants from the Medical Science Research Project of Hebei (Item No.: 20241833, 20251438), and the Science and Technology Bureau of Baoding (Item No.: 2341ZF103).</p></sec><sec><title>Author contributions</title><p>L.L.: conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, visualization, writing &#8211; original draft, writing &#8211; review &amp; editing; L.H.: data curation, formal analysis, methodology, software, validation, visualization, writing &#8211; original draft, writing &#8211; review &amp; editing; P.Z.: formal analysis, investigation, methodology, resources, software, writing &#8211; original draft; Y.X.: data curation, formal analysis, investigation, methodology, resources, software, writing &#8211; original draft, writing &#8211; review &amp; editing; D.W.: data curation, methodology, resources, writing &#8211; original draft, writing &#8211; review &amp; editing; R.S.: data curation, formal analysis, methodology, project administration, software, supervision, writing &#8211; original draft, writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest disclosure</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Guarantor</title><p>Liang Liu and Rui-Ping Su.</p></sec><sec><title>Research registration unique identifying number (UIN)</title><p>Not applicable.</p></sec><sec><title>Provenance and peer review</title><p>Not commissioned, externally peer-reviewed.</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>The datasets analyzed during the current study are available in the Surveillance, Epidemiology, and End Results (SEER) database repository (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.seer.cancer.gov" ext-link-type="uri">www.seer.cancer.gov</ext-link>).</p></sec><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>PY</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Prognostic factors influencing postoperative survival in patients with neuroendocrine carcinoma of the bladder: a population-based study</article-title>. <source>Cancer Med</source><year>2023</year>;<volume>14</volume>:<fpage>e70758</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.70758</pub-id><pub-id pub-id-type="pmcid">PMC11891926</pub-id><pub-id pub-id-type="pmid">40062660</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ullah</surname><given-names>A</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KT</given-names></name><name name-style="western"><surname>Chaudhury</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Prognostic nomogram, demographics and comparative analysis of urinary bladder small cell and large cell neuroendocrine carcinoma</article-title>. <source>Clin Genitourin Canc</source><year>2023</year>;<volume>22</volume>:<fpage>102183</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clgc.2024.102183</pub-id><pub-id pub-id-type="pmid">39236507</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Myers</surname><given-names>AA</given-names></name><name name-style="western"><surname>Fang</surname><given-names>AM</given-names></name><name name-style="western"><surname>Moussa</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder</article-title>. <source>ESMO Open</source><year>2023</year>;<volume>9</volume>:<fpage>103964</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.esmoop.2024.103964</pub-id><pub-id pub-id-type="pmcid">PMC11550343</pub-id><pub-id pub-id-type="pmid">39471563</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mollica</surname><given-names>V</given-names></name><name name-style="western"><surname>Massari</surname><given-names>F</given-names></name><name name-style="western"><surname>Andrini</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Prognostic factors of survival for high-grade neuroendocrine neoplasia of the bladder: a SEER database analysis</article-title>. <source>Curr Oncol</source><year>2022</year>;<volume>29</volume>:<fpage>5846&#8211;54</fpage>.<pub-id pub-id-type="pmid">36005199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/curroncol29080461</pub-id><pub-id pub-id-type="pmcid">PMC9406377</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agha</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>G</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Transparency In The reporting of Artificial INtelligence &#8211; the TITAN guideline</article-title>. <source>Prem J Sci</source><year>2025</year>;<volume>10</volume>:<fpage>100082</fpage>.</mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathew</surname><given-names>G</given-names></name><name name-style="western"><surname>Agha</surname><given-names>R</given-names></name><name name-style="western"><surname>Albrecht</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery</article-title>. <source>INT J SURG</source><year>2021</year>;<volume>96</volume>:<fpage>106165</fpage>.<pub-id pub-id-type="pmid">34774726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijsu.2021.106165</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer-Valuck</surname><given-names>BW</given-names></name><name name-style="western"><surname>Rao</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Henke</surname><given-names>LE</given-names></name><etal/></person-group>. <article-title>Treatment patterns and survival outcomes for patients with small cell carcinoma of the bladder</article-title>. <source>Eur Urol Focus</source><year>2017</year>;<volume>4</volume>:<fpage>900&#8211;06</fpage>.<pub-id pub-id-type="pmid">28919521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.euf.2017.09.001</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanguedolce</surname><given-names>F</given-names></name><name name-style="western"><surname>Cal&#242;</surname><given-names>B</given-names></name><name name-style="western"><surname>Chirico</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Urinary tract large cell neuroendocrine carcinoma: diagnostic, prognostic and therapeutic issues</article-title>. <source>Anticancer Res</source><year>2020</year>;<volume>40</volume>:<fpage>2439&#8211;47</fpage>.<pub-id pub-id-type="pmid">32366387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21873/anticanres.14213</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>JE</given-names></name><name name-style="western"><surname>Hoffman-Censits</surname><given-names>J</given-names></name><name name-style="western"><surname>Powles</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial</article-title>. <source>Lancet</source><year>2016</year>;<volume>387</volume>:<fpage>1909&#8211;20</fpage>.<pub-id pub-id-type="pmid">26952546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(16)00561-4</pub-id><pub-id pub-id-type="pmcid">PMC5480242</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>S</given-names></name><name name-style="western"><surname>Othus</surname><given-names>M</given-names></name><name name-style="western"><surname>Chae</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>SWOG 1609 (DART): a phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors</article-title>. <source>J Clin Oncol</source><year>2019</year>;<volume>37</volume>:<fpage>TPS2658</fpage>&#8211;<lpage>TPS2658</lpage>.</mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffman-Censits</surname><given-names>J</given-names></name><name name-style="western"><surname>Choi</surname><given-names>W</given-names></name><name name-style="western"><surname>Pal</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Urothelial cancers with small cell variant histology have confirmed high tumor mutational burden, frequent TP53 and RB mutations, and a unique gene expression profile</article-title>. <source>Eur Urol Oncol</source><year>2020</year>;<volume>4</volume>:<fpage>297&#8211;300</fpage>.<pub-id pub-id-type="pmid">32061548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.euo.2019.12.002</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>